Pharmacokinetics of tinidazole in male and female subjects.
Tinidazole is a potent nitroimidazole compound active against, and used to treat, Trichomonas vaginalis infections in males and females. Speculation exists in the literature that observed differences in tinidazole plasma concentrations between males and females may be due to sex-mediated pharmacokinetic differences. To investigate this phenomenon, a study was designed to determine the pharmacokinetics of tinidazole in male and female subjects. Six male and six female volunteers were each administered a single 2-Gm oral dose of tinidazole. Plasma and urine samples, collected over a 72-hour period, were assayed by a sensitive and specific HPLC assay. Results demonstrate a significant correlation between tinidazole oral plasma clearance and body weight and apparent volume of distribution of tinidazole and body weight for male and female subjects, respectively. There were no apparent sex-mediated differences in weight-normalized pharmacokinetic parameters as documented by statistically equivalent mean oral plasma clearances (36.1 and 35.4 ml/kg/hour), apparent volumes of distribution (0.65 and 0.63 liter/kg), and elimination half-lives (12.3 and 12.3 hours, males and females, respectively). Mean area under the tinidazole plasma concentration-versus-time curve and mean peak plasma concentration of tinidazole were 1.3 times greater for females than for males, apparently due to the smaller mean body weight of females and consequently a 1.3 times greater administered dose to the females on a weight basis.
D000328:Adult; D000704:Analysis of Variance; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006801:Humans; D008297:Male; D009593:Nitroimidazoles / Q000378:metabolism*; D011897:Random Allocation; D012044:Regression Analysis; D012737:Sex Factors; D014011:Tinidazole / Q000097:blood / Q000378:metabolism*
D009593:Nitroimidazoles; D014011:Tinidazole